Gilead announces results supporting use of Tecartus

Kite, a Gilead Company, “announced the results of four new analyses supporting the use of Tecartus in relapsed/refractory mantle cell lymphoma and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia . These results include four-year overall survival data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR T-cell therapy Tecartus in patients with R/R MCL that were presented orally at the 2023 American Society of Hematology Annual Meeting & Exposition. An analysis from ZUMA-2 showing that patients who received early versus late intervention for management of cytokine release syndrome and neurological events experienced improved safety outcomes was also presented in a poster session. In addition, real-world findings on effectiveness and safety outcomes from the Center for International Blood and Marrow Transplant Research (CIBMTR) observational database of U.S. patients who received Tecartus for R/R MCL were highlighted in an oral session; CIBMTR data from adult patients with R/R B-ALL were also presented orally today.”